Dr. Robin Schroeder Lewallen, MD

Dr. Lewallen practices at Beth Ary MD Inc in Newport Beach, California.

Dr. Lewallen's NPI, 1649533803, was assigned on June 21, 2012. Dr. Lewallen graduated from Wake Forest School of Medicine in 2012. Dr. Lewallen holds California license A144323.

Dr. Lewallen's primary practice is Beth Ary MD Inc, at 1441 Avocado Ave, Newport Beach, CA 92660 in Orange County. The practice phone is (949) 640-7200.

Dr. Lewallen's primary practice is Beth Ary MD Inc in Newport Beach, California. The medical group on file is Newport Beach Dermatology and Plastic Surgery. Dmand AI also links Dr. Lewallen to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lewallen practices. Vendor and product names are available with a free account.

Dermatology is Dr. Lewallen's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Lewallen is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Lewallen's licenses on file in 2 states: California and North Carolina.

Dmand AI lists acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, contact dermatitis, itchy rashes, psoriasis, rash and scalp rash among the conditions Dr. Lewallen treats.

CMS data shows 2,014 Medicare services from Dr. Lewallen across 13 procedure codes in 2024, for 263 Medicare patients. Medicare paid $146,409 for them. Every service was in an office.

CMS counts 263 Medicare patients who saw Dr. Lewallen in 2024. The largest group is 65 to 74, with 125 patients. 75% of them have high cholesterol, and 59% have high blood pressure. Their average risk score is 0.96, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lewallen's median patient age at 57, with 60% women.

In 2024, Dr. Lewallen wrote 307 Medicare Part D claims for 108 patients. 96% of them were for generic drugs. CMS names the drug for 192 of them, across 9 drugs with 11 or more claims each, at $3,941 in total drug cost. In 2023, CMS named 156 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Lewallen for performance year 2024, reported as part of a group. Dr. Lewallen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 713 procedures of removal of skin lesions by Dr. Lewallen, more than 90% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 9 papers to Dr. Lewallen, published from 2014 to 2016. 2014 was the busiest year, with 2. Dr. Lewallen has published most often in J Am Acad Dermatol. Dr. Lewallen's most frequent co-authors are Steven Richard Feldman, MD, Robert Milton Gathings, MD and Gil Yosipovitch, MD.

CMS Open Payments shows 75 general payments to Dr. Lewallen from 21 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Amgen Inc. paid the most, $296.

Dmand AI lists 1 award for Dr. Lewallen, most recently Resident of the year in 2016.

Dr. Lewallen graduated from Wake Forest School of Medicine in 2012.

Dr. Lewallen is in network with 9 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.